Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia

Abstract

Men with early-onset androgenetic alopecia are characterized by hormonal profiles similar to those observed in women with polycystic ovary syndrome. The purpose of this research was to investigate levels of cardiometabolic risk factors in 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)-treated men with early-onset androgenic alopecia. We studied two matched rosuvastatin-treated groups of men with mixed dyslipidemia: subjects with early-onset androgenic alopecia (group A) and subjects with normal hair growth (group B). Plasma lipids, glucose homeostasis markers, and levels of sex hormones, uric acid, hsCRP, homocysteine, fibrinogen, and 25-hydroxyvitamin D were measured before entering the study and six months later. Both groups differed in insulin sensitivity and levels of calculated bioavailable testosterone, dehydroepiandrosterone-sulfate, uric acid, hsCRP, fibrinogen, and 25-hydroxyvitamin D. Though observed in both study groups, treatment-induced reductions in total cholesterol, LDL cholesterol, hsCRP, and fibrinogen were more pronounced in group B than group A. Moreover, only in group A did rosuvastatin deteriorate insulin sensitivity, and only in group B did the drug affect uric acid, homocysteine, and 25-hydroxyvitamin D. The impact of rosuvastatin on cardiometabolic risk factors correlated with insulin sensitivity, calculated bioavailable testosterone, and dehydroepiandrosterone-sulfate. The obtained results suggest that men with early-onset androgenic alopecia may benefit to a lesser degree from rosuvastatin treatment than their peers.

Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis

“…This explanation seems, however, less likely than the previous ones. Contrary to previous studies of our research group [43,44], at entry there were no correlations between HOMA1-IR and uric acid, fibrinogen and homocysteine, while correlations with hsCRP and 25-hydroxyvitamin D were weaker than correlations between both these factors and other cardiometabolic risk factors. Moreover, there were no relationships between changes in uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin and insulin sensitivity.…”

“…Moreover, there were no relationships between changes in uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin and insulin sensitivity. This discrepancy between results of the present and of previous ones may be associated with greater insulin sensitivity in euthyroid patients with Hashimoto's thyroiditis than in subjects with hyperprolactinemia [43] or early onset androgenic alopecia [44].…”

Impaired metabolic effects of metformin in men with early-onset androgenic alopecia

“…Recently, Krysiak et al [ 22 ] have reported that rosuvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA r eductase inhibitor, strongly lowering total and LDL cholesterol levels and highly effective in the primary and secondary prevention of coronary artery disease and stroke [ 23 ], deteriorated insulin sensitivity and induced less pronounced cardiometabolic effects in men with early-onset male-pattern hair loss than in subjects with normal hair growth. Similarly, both hypotensive and pleiotropic effects of lisinopril, one of the most commonly used angiotensin-converting enzyme inhibitors [ 24 ], in hypertensive individuals were less pronounced if they had coexisting early-onset androgenic alopecia [ 25 ].…”

Impaired Cardiometabolic Effects of Bromocriptine in Men With Early‐Onset Androgenic Alopecia

“…This observation is in line with previous findings showing that individuals with early-onset androgenic alopecia benefited to a lesser degree from treatment with metformin and rosuvastatin. 18,21 Therefore, it seems that early-onset male-pattern hair loss should not be perceived merely as a cosmetic defect, as it seems to be an under-recognized entity with important clinical implications.…”

“…18,19 With common genetic background and similarities in metabolic and hormonal profiles, early-onset androgenic alopecia is regarded by some authors as the male equivalent of polycystic ovary syndrome. 14,20 The results of recent studies suggest that cardiometabolic effects of rosuvastatin in men with mixed dyslipidemia, 21 and the impact of metformin on glucose homeostasis in men at high risk for type 2 diabetes, 18 are less pronounced in the case of coexisting early-onset androgenic alopecia. Although hyperprolactinemia and early-onset male-pattern hair loss may exert an additive unfavorable effect on cardiometabolic risk, no study has been carried out to investigate dopamine agonists in patients with the simultaneous presence of both these conditions.…”